A 3-week, randomized, multicenter trial measured the efficacy of mometasone furoate 0.1% and salicylic acid 5% (MFS) for 7 days followed by mometasone furoate 0.1% (MF) for 14 days in 360 patients (mean age approx. 47 years) with psoriasis vulgaris. A second group was treated with MF alone for 21 days. The key endpoints were changes in the Psoriasis Area and Severity Index (PASI) and the Dermatology Life Quality Index (DLQI). Evaluations were made at baseline and weeks 1, 2, 3 and 4. After 1 week, the PASI scores were significantly reduced in the MFS (44%) group compared with the MF group (37%; P = 0.0017). However, there was no ...